Express Scripts (CI) announced a new electronic heath formulary this week, potentially transforming the way digital health solutions will be paid for in the near future. Back in May, the pharmacy ...

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars with competitive net costs – as preferred products on the ...

On the heels of a similar announcement from Optum Rx, pharmacy benefit management giant Express Scripts said Monday that it will add three biosimilars to its formulary to compete with Humira. The PBM ...

Express Scripts Holding, a pharmacy benefit manager that negotiates drug prices for many health plans, will launch a formulary with lower list price drugs in an effort to reduce reliance on rebates ...

Pharmacy benefit manager Express Scripts, part of Cigna's Evernorth subsidiary, will be adding Humira biosimilars to its formulary in 2023 as preferred products, which will be available to patients ...

Please provide your email address to receive an email when new articles are posted on . Starting Jan. 1, 2021, patients with inflammatory conditions who are part of the Express Scripts formulary will ...

The formulary covers over 22 million US lives. Several treatments for chronic obstructive pulmonary disease (COPD) and asthma from Boehringer Ingelheim were recently added to the Express Scripts (ESI) ...

(Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen ...

The company expects Viatris to commercialise the product in the US by year end and formulary coverage to begin in Jan 2022 Biocon Biologics Ltd (BBL) on Thursday said its interchangeable biosimilar ...

Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both ...